AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-20174498_ITM" title="Facts and information about Novartis files application for new indication for Diovan[R].">Novartis files application for new indication for Diovan[R].</a>

Close Set up an RSS feed that alerts you when new articles from Europe Intelligence Wire are available.

Frequently asked questions about RSS feeds

Novartis files application for new indication for Diovan[R].

Europe Intelligence Wire

| January 30, 2004 | COPYRIGHT 2003 Financial Times Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

(From Hugin)

Novartis files global marketing application for its leading high blood pressure drug Diovan[R], to improve survival and reduce cardiovascular events in high-risk patients following a heart attack Basel, 30 January 2004 - Novartis Pharma AG announced it has filed an application to various regulatory authorities for a new indication for Diovana (valsartan) to improve survival and reduce cardiovascular events in patients at high-risk after surviving a heart attack. The application has been submitted in the US and in Europe to the Reference Member State, Sweden, as part of the…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Novartis files blood pressure treatment Rasilez for European approval.: News wire article from: Europe Intelligence Wire September 28, 2006 700+ words
...AFX) - Novartis AG said it has filed blood pressure treatment Rasilez with the European...sustained double-digit reductions in blood pressure and reaches its maximal lowering effect...more than 7,800 patients with high blood pressure, taking Rasilez in 44 clinical trials...


Novartis files sNDA for its leading high blood pressure drug Diovan to improve...: News wire article from: Asia Africa Intelligence Wire December 22, 2003 700+ words
...Diovan is already the leading drug in its class (angiotensin II receptor blocker, or ARB) for the treatment of high blood pressure and the second leading antihypertensive agent worldwide. Located in East Hanover, NJ, Novartis Pharmaceuticals Corp is...


Novartis Files sNDA for its Leading High Blood Pressure Drug Diovan(R) to...: Press release article from: PR Newswire December 22, 2003 700+ words
...Diovan is already the leading drug in its class (angiotensin II receptor blocker, or ARB) for the treatment of high blood pressure and the second leading antihypertensive agent worldwide. All ARBs and ACE inhibitors carry a warning that the drug should...


Novartis files for approval of Rasilez.(Friday, April 21): Newspaper article from: BioWorld Week April 24, 2006 700+ words
...with other anti hypertensives for high blood pressure. A first-in-class oral product...includes data from more than 6,000 high blood pressure patients treated with SPP100 in 34...alone, Rasilez produced significant blood pressure reductions, sustained over 24 hours...


NOVARTIS FILES FOR GLOBAL INDICATION FOR DIOVAN IN THE TREATMENT OF HEART...: Press release article from: PR Newswire April 30, 2001 700+ words
...or older are hospitalized.3 High blood pressure is a common risk factor for heart failure...worldwide take Diovan for their high blood pressure. Approved in more than 80 countries...patients with either normal or high blood pressure). This press release contains forward...


Novartis files petition in Madras High Court.: News wire article from: PTI - The Press Trust of India Ltd. August 2, 2007 700+ words
Novartis files petition in Madras High Court Mumbai, Aug 2 (PTI) -- Pharma giant Novartis has filed a writ petition in Madras High Court for...


Novartis files for new use of Femara.(Brief Article): Newspaper article from: Pharma Marketletter May 17, 2004 700+ words
Switzerland's Novartis has submitted marketing applications in the USA, Canada, European Union and the UK for the use of its Femara (letrozole) in the extended adjuvant treatment of early breast cancer in postmenopausal women who have completed standard adjuvant tamoxifen therapy and remain


Novartis files Glivec for GIST in Japan.: Newspaper article from: Pharma Marketletter February 3, 2003 700+ words
Switzerland's Novartis has filed for approval to market Glivec (imatinib) in the treatment of gastrointestinal stromal tumors in Japan. The drug is already approved in Japan, the USA, Europe and a number of other world markets for chronic myeloid leukemia, and in the USA and European Union for


Novartis Files Femara Applications In North America and Europe For Indication...: Press release article from: PR Newswire May 10, 2004 700+ words
BASEL, Switzerland, May 10 /PRNewswire/ -- - Submissions based on compelling data in postmenopausal women with early breast cancer; interim published data showed extended adjuvant treatment with Femara, following standard adjuvant (post-surgery) tamoxifen, cut risk of relapse nearly in half (43%)


Novartis files pesticide petitions with EPA.: Newspaper article from: Pesticide & Toxic Chemical News May 13, 1999 700+ words
On May 5, EPA issued a notice announcing the filing of the following pesticide petitions by Novartis Crop Protection Inc., proposing to: * establish a tolerance for residues of difenoconazole ((2S,4R2R,4R) /(2S,4S) 1-(2-(4-(4-chlorophenoxy)-2-chlorophenyl)-4-methyl-

For more facts and information, see all results

The AccessMyLibrary advertising network includes: